bullish
Alphamab (康宁杰瑞) IPO: Allocation and Buy-Level for the Hot Deal
477 Views11 Dec 2019 17:20
Alphamab, the leading bispecific antibodies player in China, raised USD 220 million at HKD 10.2 per share. In this insight, we will cover the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
- Powerlong Commercial IPO Trading - Good Subscription Results but Issues Remain29 Dec 2019
- ECM Weekly (23 Dec 2019) - Bank of Guizhou, Powerlong Commercial Management23 Dec 2019
- ECM Weekly (14 Dec 2019) - SBI Cards, Poly Property, JS Global, OneConnet14 Dec 2019
- Alphamab (康宁杰瑞) IPO: Allocation and Buy-Level for the Hot Deal11 Dec 2019
- Alphamab (康宁杰瑞) IPO: You Will Likely Be Zeroed29 Nov 2019
- Alphamab (康宁杰瑞) Pre-IPO: Promising Readings from PHIP Updates18 Nov 2019
x